NICE Lets Astellas Pharma’s Betmiga Pass, But On A Restricted Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE gives the nod to Astellas Pharma’s Betmiga for overactive bladder control due to its cost-effectiveness but nevertheless restricts its indication because it’s not superior to existing therapies.